Pharmaceutical Technology Europe
The biggest differences between the development of a biosimilar and a generic medicine lie primarily in the preclinical and clinical stages.
Huub Schellekens
Advertisement
Huub Schellekens is Professor in the Department of Pharmaceutical Sciences and Innovation Studies at Utrecht University, The Netherlands.
Articles by Huub Schellekens
Advertisement
Latest Updated Articles
- What Is Hindering The Uptake Of Biosimilars?
August 1st 2010
Advertisement
Advertisement